Background. Stratification of glioma according to isocitrate dehydrogenase 1/2 (IDH1/2) mutation and 1p/19q codeletion status has gained major importance in the new World Health Organization (WHO) classification. Parameters derived from uptake dynamics of 18 F-fluoro-ethyl-tyrosine PET ( 18 F-FET-PET) such as minimal time-to-peak (TTP min ) allow discrimination between different prognostic glioma subgroups, too. The present study is aimed at exploring whether TTP min analysis provides prognostic information beyond the WHO classification. Methods. Three hundred patients with newly diagnosed WHO 2007 grades II-IV gliomas with 18 F-FET-PET imaging at diagnosis were grouped into 4 subgroups (IDH1/2 mut-1p/19q codel; IDH1/2 mut-1p/19q non-codel; IDH1/2 wildtype WHO grade II and III tumors; and glioblastoma). Clinical and imaging factors such as age, Karnofsky performance score, treatment, TTP min , and maximal tumor-to-brain ratio (TBR max ) were analyzed with regard to progression-free and overall survival (PFS and OS) via univariate and multivariate regression analysis. Results. PFS and OS were longest in the IDH1/2 mut-1p/19q codel subgroup, followed by IDH1/2 mut-1p/19q noncodel, IDH1/2 wildtype, and GBM (P < 0.001). Further, outcome stratified by TTP min with a cutoff of 17.5 minutes revealed significantly longer PFS and OS in patients with TTP min >17.5 minutes (P < 0.001 for PFS and OS). Lower TBR max values or the absence of 18 F-FET uptake was also associated with favorable outcome in the entire group. In the subgroup analyses, longer median TTP min was associated with improved outcome specifically in the IDH1/2 mut-1p/19q non-codel group. Conclusion. 18 F-FET-PET-derived dynamic analysis defines prognostically distinct subgroups of IDH1/2 mutant1p/19q non-codel gliomas which cannot be distinguished as yet by molecular marker analysis.
Tailoring treatment options in glioma patients according to an individual risk profile is gaining increasing importance in the field of neuro-oncology. 1 Recent analyses of large cohort studies have uncovered a dominant association of molecular markers with clinical outcome in glioma patients. [2] [3] [4] [5] As a consequence, the 2016 revision of the World Health Organization (WHO) classification of tumors of the central nervous system accounts for molecular markers for subclassification of gliomas. 6 Isocitrate dehydrogenase 1 and 2 (IDH1/2) mutant tumors have a different biology and better outcome than IDH1/2 wildtype (wt) tumors, and IDH1/2 mutant tumors are further subdivided into 1p/19q codeleted (associated with oligodendroglial morphology and better outcome) and non-codeleted tumors (associated with astrocytic morphology and intermediate outcome).
Recent advances in molecular imaging via O-(2-18 Ffluorethyl)-L-tyrosine PET ( 18 F-FET-PET) have led to the establishment of several non-invasive, imaging-derived prognostic factors such as biological tumor volume and dynamic tracer uptake represented by time activity curves (TACs) and time-to-peak (TTP) evaluation. [7] [8] [9] In particular the dynamic evaluation of uptake including TTP analysis is highly associated with prognosis across WHO grades II-IV gliomas. 8, 9 Aim of this study was to explore whether imaging-derived markers such as TTP still add to the profoundly improved prognostic classification realized within the framework of the updated WHO classification. 6 
Materials and Methods

Patient Evaluation
Patients with a supratentorial grade II-IV glioma (WHO 2007 ) diagnosed between 2004 and 2014 who had undergone 18 F-FET-PET with static and dynamic analysis prior to histopathological diagnosis were retrospectively identified. The study was approved by the institutional review board (approval number: 604-16) and all subjects signed written informed consent as part of the clinical routine. PFS was measured from the date of surgical procedure to the first event of clinical deterioration-that is, new neurological symptoms, worsening as indicated by KPS, an increase in steroid medication, or tumor growth on conventional MRI according to the modified Response Assessment in Neuro-Oncology criteria. 10 Overall survival (OS) was correspondingly calculated from date of surgery to date of death. Date of last follow-up was December 2016.
F-FET-PET and MR Imaging
Dynamic 18 F-FET-PET scans were acquired with an ECAT EXACT HR+ scanner (Siemens Healthcare) according to standard protocols after slow intravenous bolus injection of 180 MBq 18 F-FET. 8 Dynamic emission recording in 3D mode consisted of 16 frames (7 × 10 s, 3 × 30 s, 1 × 2 min, 3 × 5 min, and 2 × 10 min) and was conducted until 40 minutes post injection. For further evaluation, images were transferred to a HERMES workstation (Hermes Medical Solutions).
In the semiquantitative analysis, the maximal tumoral 18 F-FET uptake corrected for mean background activity in the contralateral hemisphere (maximal tumor-to-brain ratio, TBR max ) was evaluated. Tumors were termed 18 F-FET "positive" when TBR max was above 1.6. 11,12 For the dynamic analysis, which was performed using HERMES PET Display Dynamic, 90% isocontour regions of interest were semiautomatically drawn on each individual slice throughout the tumor in the 10-30 minutes summation images and afterward applied to the dynamic PET data in order to extract the TAC. For each extracted TAC within the tumor, the peak of the curve was identified and the time of peak uptake was noted and set as TTP. This procedure was repeated for all slices throughout the tumor. As explained in detail previously, 8 the shortest TTP being present in at least 2 adjacent slices was defined as minimal TTP (TTP min ).
MR imaging was performed prior to tissue sampling according to standard protocols and included acquisition of axial T 2 -weighted sequences as well as 3D T1-weighted sequences before and after administration of intravenous contrast agent (0.1 mmol/kg gadobenate dimeglumine, MultiHance, Bracco Imaging). Progression was diagnosed whenever (i) any new contrast enhancement (CE) was noted in a previously non-enhancing tumor or (ii) T 2 diameter of the tumor enlarged above 25%. Contrast enhancement (yes/no) as well as tumor size and volume (both CE and T 2 -based size/volume) were assessed on initial MRIs prior to surgical procedure using Brainlab software (iPlan, Brainlab).
Surgical Procedure
Biopsy or resection was performed according to interdisciplinary tumor board recommendations and patient's preference. The stereotactic biopsy procedure at our institution has been described previously. Briefly, multiple tumor tissue specimens were obtained from the area of
Importance of the study
In light of the revised WHO 2016 classification, management of gliomas will increasingly depend on their molecular genetic profile. Data from more refined imaging techniques, such as the dynamic 18 F-FET-PET uptake analysis discussed in this manuscript, indicate that imaging biomarkers might provide additional information relevant for prognosis. The current manuscript explores the value of dynamic 18 F-FET-PET in 300 patients with a newly diagnosed WHO grade II-IV glioma; our data show dynamic uptake analysis reflected by TTP to provide further prognostic information within molecular subgroups according to IDH1/2 mutation and codeletion of 1p/19q independently of WHO grading.
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the highest 18 F-FET uptake. 13, 14 The microsurgical resection procedure involved MRI-and 18 F-FET PET-based neuronavigation (Brainlab).
Histopathology and Molecular Genetic Markers
Histological diagnosis was performed by experienced neuropathologists (U.S., A.G.) according to the WHO 2007 classification blinded for PET and MRI findings. 15 Determination of O 6 -DNA methylguanine-methyltransferase (MGMT) promoter methylation was performed using methylation-specific PCR. 16 Codeletion of 1p/19q was analyzed according to standard protocols 17 with the following microsatellite markers: D1S548, D1S1184, D1S1608, D1S1592, D1S1161, D19S601, D19S559, D1S433, D19S718, and D19S431. Determination of IDH1 mutation was performed using pyrosequencing of an 88-bp-long fragment of the IDH1 gene including the mutation hotspot at codon 132, while for IDH2 mutations, pyrosequencing was performed on an 83-bp-long fragment of the IDH2 gene including the mutation hotspot at codon 172.
Patients' diseases were categorized as either glioblastoma (GBM) or glioma WHO grades II and III, the latter 2 groups differentiated by mutational status of IDH1/2 and codeletion of 1p/19q.
Statistical Analysis
SPSS for Windows v21.0 was used for statistical calculations. Progression-free survival (PFS) and OS were analyzed with the Kaplan-Meier method; when median PFS or OS times were not reached, mean values were given and used for analysis. The distribution of patient-and tumorrelated variables was analyzed by chi-squared statistics (for categorical variables) and the Mann-Whitney U-test (for continuously scaled variables). The median was used as threshold for dichotomization of parameters. For univariate prognostic analyses, all parameters were evaluated using Cox regression. Covariates significant in one-variable models were then evaluated in multivariate analyses using a stepwise backward exclusion model. In case of an intercorrelation of most relevant covariates, alternative models were tested and compared by computing the maximized likelihoods. A 2-tailed P-value <0.05 was considered significant. Figure S1 . Detailed data on each patient are given in Supplementary Table S2 . Radiochemotherapy 100
Results
Patient Characteristics
F-FET-PET and MRI Correlates of Outcome
Initial median tumor size as assessed by T 2 -MRI was 49 mL; there was no significant difference in tumor size within the 4 tumor groups (P = 0.33). Contrast enhancement was observed in 172/300 (57%) of tumors; all GBM patients presented with CE, while presence of CE was equally distributed among the 3 remaining molecular groups (P = 0.25). In 18 F -FET-PET, 255 of 300 (85%) tumors had an elevated 18 F-FET uptake and thus were classified as 18 F-FET positive. The rates of 18 F-FET− lesions per molecular subgroup were: 3/58 (5%) for IDH1/2 mut1p/19q codel tumors, 28/79 (35%) for IDH1/2 mut-1p/19q non-codel tumors, 9/76 (11.8%) for IDH1/2 wt tumors, and 0/73 for GBM ( Table 2 ). In the entire group, a negative 18 F-FET-PET was associated with prognosis: PFS and OS times in patients with 18 F-FET− tumors were much longer compared with patients with 18 F-FET+ tumors (P = 0.01 and 0.001).
Dynamic analysis of tracer uptake could be performed in only 18 F-FET positive tumors. TTP min analysis was therefore not available in the 45 18 F-FET− cases and in a further 5 patients for technical reasons. Thus, the following calculations refer to a study population of 255 patients. Correlation of continuously scaled TBR max and TTP min with PFS or OS revealed shorter (P < 0.001) PFS and OS in patients with higher TBR max and shorter TTP min values. Longer TTP min was highly correlated with the presence of IDH1/2 mutation (P < 0.001). In order to identify different prognostic subgroups, median values for TBR max and TTP min were calculated within the entire 18 FET positive patient population as well as in subgroups defined by molecular markers. PFS and OS were compared between patient groups split by this median. Table 2) .
Median TTP min was 17.5 minutes for all patients; patients with a TTP min >17.5 minutes had longer PFS and OS than patients with a TTP min ≤17.5 minutes: median PFS not reached versus 14.2 months (95% CI: 11.1-17.3)/(log-rank P < 0.001) and median OS not reached versus 26.2 months (95% CI: 21.6-30.8)/(log-rank P < 0.001).
Next, we assessed the correlation with outcome of 18 F-FET-PET parameters within the molecular subgroups defined by IDH1/2 mutation, 1p/19q codeletion status, and GBM histology according to the WHO 2016 classification. 6 
IDH1/2 Mutant-1p/19q Codeleted Group
In this subgroup, neither presence nor absence of 18 F-FET uptake nor TBR max nor TTP min discriminated between outcome of patients. Median TBR max was 2.7 in this subgroup and median TTP min was 25 minutes. There was no significant OS difference between tumors with a TTP min >25 and those with a TTP min of ≤25 minutes (log-rank P = 0.54 for PFS and P = 0.92 for OS; Table 2 , Fig. 1A/B ).
IDH1/2 Mutant-1p/19q Non-Codeleted Group
In this subgroup, 18 F-FET-uptake per se (positive versus negative) did not correlate with outcome, while the magnitude of 18 F-FET uptake did. Patients with TBR max values ≤1.7 (in-group median) had a significantly longer PFS time and slightly longer OS time compared with those with TBR max values >1.7 (Table 2) . Furthermore, outcome analysis according to the in-group median TTP min of 25 minutes revealed patients with a TTP min >25 minutes to have a significantly better outcome for both PFS and OS ( Table 2 , Fig. 1C/D) . A comparison of clinical parameters between these 2 patient groups with different outcomes revealed no distinguishing feature apart from a different distribution of TTP min between the WHO grades (Supplementary Table S3 ). Interestingly, patients with a TTP min >25 minutes had a better outcome than patients with a TTP min ≤25 minutes irrespective of WHO grade II or III (Fig. 3B) . Median TBR max did not provide a comparable separation (Fig. 3C) . An example of a patient with grade III tumor/TTP min >25 and favorable outcome as opposed to poor outcome in a patient with a grade II tumor and TTP min ≤25 minutes is illustrated in Supplementary Fig. S2 .
IDH1/2 Wildtype Group (WHO grades II and III)
Neither 18 F-FET uptake (positive versus negative) nor median TBR max of 2.5 was associated with outcome (Table 2) . Furthermore, outcome analysis according to median TTP min of 12.5 minutes in IDH1/2 wt tumors showed no difference in PFS and OS times between patients with a TTP min ≤12.5 compared with those with a TTP min >12.5 minutes (P = 0.51 and P = 0.14, respectively; Table 2 , Fig. 2A/B) .
GBM Group
All tumors within this subgroup were 18 FET positive. Neither the median TBR max of 3.6 nor the median TTP min of 12.5 minutes was associated with outcome. However, while not reaching statistical significance, with 23.1 months compared with 12.8 months, patients with a TTP min >12.5 minutes had a considerably longer OS time (P = 0.29; Fig. 2D ).
Univariate and Multivariate Survival Analysis (all patients)
Univariate analysis revealed lower age, higher KPS, delay of cytotoxic therapy, lower WHO grade, and presence of IDH1/2 mutation to be highly associated with both PFS and OS in the entire group (Table 3) . Absence of CE on initial MRI, absence of 18 F-FET uptake, lower TBR max , and a TTP min >17.5 minutes were also associated with longer PFS and OS.
Multivariate analysis was conducted using all parameters with P < 0.05 in the univariate analysis. Lower WHO grade and presence of IDH1/2 mutation were associated with prolonged PFS. In addition to WHO grade and IDH1/2 mutation, TTP min >17.5 minutes was an independent prognostic factor for improved survival (see Table 3 ). Subgroup analysis could not be performed due to low number of events in the 2 IDH1/2 mutated groups.
Discussion
Since the molecular markers IDH1/2 mutation and 1p/19q codeletion have been identified to be strongly associated with prognosis, [1] [2] [3] [4] [5] [18] [19] [20] the 2016 revision of the WHO Classification of Tumors of the Central Nervous System has implemented a classification scheme for gliomas based on these molecular markers. 6 This might affect therapeutic approaches in the future by allowing stronger emphasis on individual, tumor-tailored therapies based on molecular profiling. Accordingly, amino acid PET has been shown to provide valuable information regarding differential diagnosis of cerebral lesions as well as prognosis among gliomas. 8, 9, 12, 21, 22 Dynamic analysis of 18 F-FET uptake using TTP min analysis discriminates patients with poor or favorable prognosis at the time of diagnosis in gliomas across WHO 2007 grades II to IV. 8, 9 In light of the revision of the WHO classification, we sought to reassess the information derived from dynamic analysis of 18 F-FET-PET within the framework of a glioma classification in adults largely based on IDH1/2 mutation and 1p/19q codeletion.
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As a principal observation, longer TTP min correlates with longer OS independently of grading and the presence of IDH1/2 mutation in our entire study population. Notably, in IDH1/2 mut-1p/19q non-codel gliomas, TTP min provides an additional prognostic marker, emphasizing the value of PET in these tumors.
The biological mechanism of tracer kinetics leading to short or long TTP min is not fully understood yet. 23 18 F-FET uptake depends on a bidirectional L-type amino acid transporter (LAT1/2) expressed in the cell membrane and vasculature of gliomas. Its expression level was found to correlate with the degree of malignancy according to the WHO 2007 classification: Pooled grades III and IV gliomas had much higher LAT1 expression than grade II gliomas. 24 Moreover, overexpression of LAT1 in glioma cells with low endogenous LAT1 expression enhanced tumor growth in nude mice. 24 After intracellular uptake, 18 F-FET is not incorporated into proteins or trapped within the tumor cell but washed out after a certain period of time. 23 The faster the 18 F-FET uptake, the faster it is washed out of the tumor cell. A higher tracer turnover might be influenced by either a higher LAT1/2 expression or higher tracer availability due to increased tumor vascularity/perfusion. High vascularity and an elevated ratio of LATs have been reported for grades III and IV gliomas, and both might contribute to this observation. Both patients with IDH1/2 wt grades II and III tumors as well as patients with GBM have the shortest median TTP min of 12.5 minutes. In the GBM subgroup, patients with a TTP min >12.5 minutes have a considerably longer survival time of 23.1 months compared with 12.8 months in patients with a TTP min ≤12.5. In the other group also known to display higher perfusion, namely the IDH1/2 mut-1p/19 q codel tumors, we did not detect TTP min as a prognostic factor, which might be due to a limited number of events. One could speculate whether high perfusion might interfere with effects of TTP min in these 2 highly vascularized tumor groups. Interestingly, different perfusion properties were shown to be associated with both outcome and presence of IDH1/2 mutation in astrocytic tumors by Kickingereder et al. 25 These authors found an overactivation of pro-angiogenic pathways in IDH1/2 wt tumors, well explaining the observed difference in relative cerebral blood volume in the different molecular subgroups and demonstrating the potential additional value of imaging biomarkers. As TTP min was associated with survival in tumors being IDH1/2 mutated without 1p/19q codeletion, both TTP min and perfusion might be surrogates of a distinct biological tumor property. Further studies combining dynamic PET and perfusion-based MRI may help elucidate the interaction between perfusion, vascularity, and TTP min . 
In contrast to TTP min , TBR max was associated with prognosis in the 2 IDH1/2 mutant groups. OS was longer, albeit not significant, in IDH1/2 mut-1p/19q codel patients with TBR max ≤2.7 (P = 0.07) and PFS was significantly longer in the non-codel tumors with TBR max ≤1.7 (P = 0.01). Hence, the magnitude of 18 F-FET uptake might be associated with histological features such as cell density, mitotic index, and vascularization and thus most likely reflects WHO grade. 26 The factor " 18 F-FET-negative" was associated with favorable outcome in the entire group; however, this could be attributed to the high intercorrelation with the molecular subtype: 18 F-FET− tumors were most often found among the IDH1/2 mut-1p/19q non-codel (astrocytic) tumor type, while 95% of IDH1/2 wt tumors were 18 F-FET positive.
Although counterintuitive, the factor " 18 F-FET-negative" lost its significance within the group of IDH1/2 mut-1p/19q non-codel tumors, and could not be evaluated in the remaining 2 groups due to small number of 18 F-FET− cases. So far, the underlying mechanisms leading to complete lack of 18 F-FET uptake are not understood; one explanation might be the lack or an inactivity of LATs in a proportion of IDH1/2 mut-1p/19q non-codel tumors (approximately onethird of our astrocytic tumor population) and remains to be addressed in further studies.
Limitations of the study arise from the retrospective study design and heterogeneous surgical and postsurgical management strategies.
Furthermore, TBR max values as well as determination of TTP min are dependent on scanner resolution and data processing, with the consequence that absolute values may not be comparable between different centers. 22, 27 A standardization of data processing and evaluation will help to improve comparability.
Altogether, dynamic analysis of 18 F-FET tracer uptake using TTP min discriminates patients with favorable and poor prognosis within the molecular defined subgroup of IDH1/2 mut-1p/19q non-codel tumors, most of which are now classified as astrocytomas. Thus, this might be an imaging biomarker providing additional prognostic information to stratify astrocytoma patients into low-risk and high-risk groups.
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